• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/12/25 4:27:42 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email
    8-K
    false000165824700016582472025-06-112025-06-11

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 11, 2025

     

     

    Crinetics Pharmaceuticals, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38583

    26-3744114

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    6055 Lusk Boulevard

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 450-6464

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    CRNX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. (the “Company”) was held online via live audio webcast on June 11, 2025 (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 88,931,596 shares of common stock, or approximately 95% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting are as follows:

    Proposal One - Election of Directors

     

    The Company’s stockholders approved the election of three Class I directors to the Board of Directors for three-year terms to expire at the 2028 annual meeting of stockholders. The results of such vote were:

     Votes For

     Votes Withheld

    Broker Non-Votes

    R. Scott Struthers, Ph.D.

    69,586,919

    15,729,147

    3,615,529

    Matthew K. Fust

    67,615,092

    17,700,974

    3,615,529

    Rogério Vivaldi Coelho, M.D.

    68,864,528

    16,451,538

    3,615,529

    Proposal Two - Ratification of Selection of Independent Registered Accounting Firm

     

    The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2025. The results of such vote were:

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    88,742,805

    129,064

    59,727

    0

    Proposal Three - Approval, on an advisory basis, of the compensation of the Company’s named executive officers

     

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    82,658,715

    2,636,436

    20,915

    3,615,529

     

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Crinetics Pharmaceuticals, Inc.

     

     

     

     

    Date:

    June 12, 2025

    By:

    /s/ R. Scott Struthers, Ph.D.

     

     

     

    R. Scott Struthers, Ph.D.
    President and Chief Executive Officer

     


    Get the next $CRNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    1/12/2026$67.00Neutral → Buy
    Goldman
    7/10/2025$36.00Neutral
    Goldman
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    1/16/2024$50.00Overweight
    Morgan Stanley
    More analyst ratings

    $CRNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December       Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026       Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates               Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relate

    2/26/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

    SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the C

    2/5/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,

    1/26/26 5:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    SEC Filings

    View All

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    3/3/26 4:07:22 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Crinetics Pharmaceuticals Inc.

    144 - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    3/2/26 10:28:28 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Crinetics Pharmaceuticals Inc.

    S-8 - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    2/26/26 4:37:47 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Okey Stephanie sold $119,010 worth of shares (3,000 units at $39.67), decreasing direct ownership by 18% to 13,300 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    3/4/26 5:44:48 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Schilke Tobin sold $266,305 worth of shares (6,713 units at $39.67), decreasing direct ownership by 8% to 78,121 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    3/4/26 5:43:52 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Struthers Richard Scott was granted 62,000 shares, increasing direct ownership by 17% to 426,759 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    2/25/26 4:37:01 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crinetics Pharmaceuticals upgraded by Goldman with a new price target

    Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00

    1/12/26 7:47:46 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Crinetics Pharmaceuticals with a new price target

    Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00

    7/10/25 8:53:33 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Crinetics Pharmaceuticals with a new price target

    Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    3/25/25 8:26:55 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Leadership Updates

    Live Leadership Updates

    View All

    Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

    2/24/25 8:30:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

    SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D

    12/16/24 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

    SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg

    5/30/24 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

    SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 1:22:38 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Financials

    Live finance-specific insights

    View All

    Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,

    1/26/26 5:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

    Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr

    1/5/26 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

    SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast DetailsManagement will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible

    1/4/26 4:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care